Differential binding domains of peptide and non-peptide ligands in the cloned rat kappa opioid receptor.

[1]  S. St.-Pierre,et al.  Dynorphin-(1-13). I. Structure-function relationships of Ala-containing analogs. , 2009, International journal of peptide and protein research.

[2]  G. Pasternak,et al.  An opiate-receptor gene family reunion , 1994, Trends in Neurosciences.

[3]  G. Bell,et al.  Molecular biology of opioid receptors , 1993, Trends in Neurosciences.

[4]  C. Chen,et al.  Molecular cloning and expression of a rat kappa opioid receptor. , 1993, The Biochemical journal.

[5]  Lei Yu,et al.  Molecular cloning and functional expression of a mu opioid receptor from rat brain , 1994, Regulatory Peptides.

[6]  C. Strader,et al.  Amino–aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345 , 1993, Nature.

[7]  C. Strader,et al.  Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor. , 1992, The Journal of biological chemistry.

[8]  C. Strader,et al.  Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580. , 1992, The Journal of biological chemistry.

[9]  R. Edwards,et al.  Cloning of a delta opioid receptor by functional expression. , 1992, Science.

[10]  K. Befort,et al.  The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Strader,et al.  The extracellular domain of the neurokinin-1 receptor is required for high-affinity binding of peptides. , 1992 .

[12]  H. Yamamura,et al.  Chimeric M1/M2 muscarinic receptors: correlation of ligand selectivity and functional coupling with structural modifications. , 1992, Journal of Pharmacology and Experimental Therapeutics.

[13]  S. Ho,et al.  Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. , 1989, Gene.

[14]  M. Caron,et al.  Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P. Portoghese,et al.  Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. , 1988, The Journal of pharmacology and experimental therapeutics.

[16]  C. Strader,et al.  Structural features required for ligand binding to the beta‐adrenergic receptor. , 1987, The EMBO journal.

[17]  A. Lipkowski,et al.  Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. , 1987, Life sciences.

[18]  Irving S. Sigal,et al.  Ligand binding to the β-adrenergic receptor involves its rhodopsin-like core , 1987, Nature.

[19]  J. Mccall,et al.  [3H]U-69593 a highly selective ligand for the opioid κ receptor , 1985 .

[20]  R. Houghten,et al.  alpha-Neo-endorphin: receptor binding properties of the tritiated ligand. , 1983, Life sciences.

[21]  G A McPherson,et al.  A practical computer-based approach to the analysis of radioligand binding experiments. , 1983, Computer programs in biomedicine.

[22]  C. Chavkin,et al.  Dynorphin is a specific endogenous ligand of the kappa opioid receptor. , 1982, Science.

[23]  A Goldstein,et al.  Specific receptor for the opioid peptide dynorphin: structure--activity relationships. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[24]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Childers.  Opioid receptor-coupled second messenger systems , 1991 .

[26]  H. Loh,et al.  Molecular characterization of opioid receptors. , 1990, Annual review of pharmacology and toxicology.

[27]  B. Cullen.  Use of eukaryotic expression technology in the functional analysis of cloned genes. , 1987, Methods in enzymology.

[28]  A. Goldstein,et al.  Opioid receptor selectivity of dynorphin gene products. , 1984, The Journal of pharmacology and experimental therapeutics.

[29]  R. Lahti,et al.  U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. , 1983, The Journal of pharmacology and experimental therapeutics.